Table 4.

Association of donor YKL-40 with risk of recipient DGF, stratified by AKI status

Tertile of YKL-40 (Range [ng/ml])NRate of DGF (%)RR (95% CI)
UnadjustedAdjusted for Donor VariablesaAdjusted for Donor, Transport, and Recipient VariablesbAdjusted for Donor, Transport, Recipient Variables, and Donor NGALc
Donors without AKI
 T1 (<0.61)n1=853240 (28)1.0 (referent)1.0 (referent)1.0 (referent)1.0 (referent)
 T2 (0.61–3.31)n2=796226 (28)1.01 (0.86 to 1.20)0.93 (0.80 to 1.09)0.92 (0.79 to 1.08)0.88 (0.75 to 1.03)
 T3 (3.33–432.78)n3=592187 (32)1.13 (0.95 to 1.34)0.96 (0.82 to 1.14)0.91 (0.77 to 1.07)0.79 (0.65 to 0.97)
Donors with AKI
 T1 (<0.61)n1=2316 (70)1.0 (referent)1.0 (referent)1.0 (referent)1.0 (referent)
 T2 (0.61–3.31)n2=3214 (44)0.64 (0.39 to 1.06)0.63 (0.39 to 1.01)0.59 (0.38 to 0.91)0.57 (0.37 to 0.89)
 T3 (3.33–432.78)n3=13973 (53)0.76 (0.53 to 1.08)0.65 (0.46 to 0.93)0.66 (0.47 to 0.91)0.51 (0.32 to 0.80)
  • Donor AKI was defined as at least a doubling of serum creatinine from admission to the terminal value. There was a significant interaction between the highest urinary YKL-40 tertile and AKI (P=0.05) in unadjusted analyses.

  • a Donor variables used for adjustment: age (years), height (cm), weight (kg), black race, history of hypertension, history of diabetes, terminal serum creatinine, stroke as cause of death, and donation after circulatory determination of death status.

  • b Includes all variables listed above plus the following transport and recipient variables: cold ischemia time (hours), age (years), black race, gender, previous kidney transplant, diabetes as the cause of ESRD, number of human leukocyte antigen mismatches, body mass index (kg/m2), duration of dialysis before transplant (months), and panel reactive antibody (%).

  • c Includes all variables listed above plus log base 2–transformed donor urine NGAL.